EU/US Properties Organoleptics Cosmetics Suppliers Safety Safety in use Safety references References Other Blenders Uses Occurrence Synonyms Articles Notes
 

bis(maltolato)oxovanadium(IV)
vanadium, bis(3-hydroxy-2-methyl-4H-pyran-4-onato-O3,O4)oxo-, (SP-5-31)-

Supplier Sponsors

Name:2-methyl-4-oxopyran-3-olate; oxovanadium(2+)
CAS Number: 38213-69-3Picture of molecule3D/inchi
FDA UNII: HA933D78YW
Molecular Weight:317.14760000
Formula:C12 H10 O7 V
NMR Predictor:Predict (works with chrome, Edge or firefox)
Category:nutrient supplements: EFSA: safety cannot be established
 
US / EU / FDA / JECFA / FEMA / FLAVIS / Scholar / Patent Information:
Google Scholar:Search
Google Books:Search
Google Scholar: with word "volatile"Search
Google Scholar: with word "flavor"Search
Google Scholar: with word "odor"Search
Perfumer and Flavorist:Search
Google Patents:Search
US Patents:Search
EU Patents:Search
Pubchem Patents:Search
PubMed:Search
NCBI:Search
 
Physical Properties:
Assay: 98.00 to 100.00
Food Chemicals Codex Listed: No
Boiling Point: 284.70 °C. @ 760.00 mm Hg (est)
Vapor Pressure:0.000337 mmHg @ 25.00 °C. (est)
Flash Point: 261.00 °F. TCC ( 127.30 °C. ) (est)
logP (o/w): 0.079 (est)
 
Organoleptic Properties:
Odor and/or flavor descriptions from others (if found).
 
Cosmetic Information:
None found
 
Suppliers:
BOC Sciences
For experimental / research use only.
Bis(maltolato) oxovanadium(IV) 95%
Carbosynth
For experimental / research use only.
Bis(maltolato)oxovanadium(IV)
Santa Cruz Biotechnology
For experimental / research use only.
Bis(maltolato)oxovanadium(IV)
Sigma-Aldrich: Sigma
For experimental / research use only.
BMOV ≥95% (elemental analysis)
sds
 
Safety Information:
Preferred SDS: View
 
Hazards identification
 
Classification of the substance or mixture
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS)
None found.
GHS Label elements, including precautionary statements
 
Pictogram
 
Hazard statement(s)
None found.
Precautionary statement(s)
None found.
Oral/Parenteral Toxicity:
Not determined
Dermal Toxicity:
Not determined
Inhalation Toxicity:
Not determined
 
Safety in Use Information:
Category:
nutrient supplements: EFSA: safety cannot be established
Recommendation for bis(maltolato)oxovanadium(IV) usage levels up to:
 not for fragrance use.
 
Recommendation for bis(maltolato)oxovanadium(IV) flavor usage levels up to:
 not for flavor use.
 
Safety References:
European Food Safety Authority (EFSA) reference(s):

Vanadium citrate, bismaltolato oxo vanadium and bisglycinato oxo vanadium added for nutritional purposes to foods for particular nutritional uses and foods (including food supplements) intended for the general population and vanadyl sulphate, vanadium pentoxide and ammonium monovanadate added for nutritional purposes to food supplements [1] - Scientific Opinion of the Panel on Food Additives, Flavourings, Processing Aids and Materials in Contact with Food
View page or View pdf

AIDS Citations:Search
Cancer Citations:Search
Toxicology Citations:Search
EPA ACToR:Toxicology Data
EPA Substance Registry Services (SRS):Registry
Laboratory Chemical Safety Summary :3035454
National Institute of Allergy and Infectious Diseases:Data
WGK Germany:3
2-methyl-4-oxopyran-3-olate; oxovanadium(2+)
Chemidplus:0038213693
 
References:
 2-methyl-4-oxopyran-3-olate; oxovanadium(2+)
NIST Chemistry WebBook:Search Inchi
Pubchem (cid):3035454
Pubchem (sid):135076442
 
Other Information:
(IUPAC):Atomic Weights of the Elements 2011 (pdf)
Videos:The Periodic Table of Videos
tgsc:Atomic Weights use for this web site
(IUPAC):Periodic Table of the Elements
HMDB (The Human Metabolome Database):Search
FDA Listing of Food Additive Status:View
ChemSpider:View
 
Potential Blenders and core components note
None Found
 
Potential Uses:
None Found
 
Occurrence (nature, food, other):note
 not found in nature
 
Synonyms:
 BMOV(IV)
2-methyl-4-oxopyran-3-olate; oxovanadium(2+)
 vanadium, bis(3-hydroxy-2-methyl-4H-pyran-4-onato-O3,O4)oxo-, (SP-5-31)-
 

Articles:

PubMed:Oxovanadium-based inhibitors can drive redox-sensitive cytotoxicity in neuroblastoma cells and synergise strongly with buthionine sulfoximine.
PubMed:Exposure to bis(maltolato)oxovanadium(IV) increases levels of hepcidin mRNA and impairs the homeostasis of iron but not that of manganese.
PubMed:Changes in iron metabolism and oxidative status in STZ-induced diabetic rats treated with bis(maltolato) oxovanadium (IV) as an antidiabetic agent.
PubMed:Speciation studies of vanadium in human liver (HepG2) cells after in vitro exposure to bis(maltolato)oxovanadium(IV) using HPLC online with elemental and molecular mass spectrometry.
PubMed:Aggravation by vanadium of magnesium deficiency in STZ-induced diabetic rats.
PubMed:Bis(acetylacetonato)-oxovanadium(iv), bis(maltolato)-oxovanadium(iv) and sodium metavanadate induce antilipolytic effects by regulating hormone-sensitive lipase and perilipin via activation of Akt.
PubMed:Changes in the antioxidant defence and in selenium concentration in tissues of vanadium exposed rats.
PubMed:The anti-diabetic bis(maltolato)oxovanadium(IV) decreases lipid order while increasing insulin receptor localization in membrane microdomains.
PubMed:Inhibition of protein tyrosine phosphatase improves angiogenesis via enhancing Ang-1/Tie-2 signaling in diabetes.
PubMed:Vanadium compounds affect growth and morphology of human rhabdomyosarcoma cell line.
PubMed:Biotransformation of BMOV in the presence of blood serum proteins.
PubMed:Effect of bis(maltolato)oxovanadium (IV) (BMOV) on selenium nutritional status in diabetic streptozotocin rats.
PubMed:Bioavailability, tissue distribution and hypoglycaemic effect of vanadium in magnesium-deficient rats.
PubMed:Absorption, transport and insulin-mimetic properties of bis(maltolato)oxovanadium (IV) in streptozotocin-induced hyperglycemic rats by integrated mass spectrometric techniques.
PubMed:Antidiabetic vanadium compound and membrane interfaces: interface-facilitated metal complex hydrolysis.
PubMed:Vibrational spectra of bis(maltolato)oxovanadium(IV): a potent insulin mimetic agent.
PubMed:Study of the antidiabetic capacity of the VO(dmpp)2 complex.
PubMed:Antidiabetic Bis-Maltolato-OxoVanadium(IV): conversion of inactive trans- to bioactive cis-BMOV for possible binding to target PTP-1B.
PubMed:Effects of decavanadate and insulin enhancing vanadium compounds on glucose uptake in isolated rat adipocytes.
PubMed:Bis(maltolato)-oxovanadium (IV)-induced phosphorylation of PKB, GSK-3 and FOXO1 contributes to its glucoregulatory responses (review).
PubMed:Vanadium treatment of type 2 diabetes: a view to the future.
PubMed:Calorimetric studies of the interaction between the insulin-enhancing drug candidate bis(maltolato)oxovanadium(IV) (BMOV) and human serum apo-transferrin.
PubMed:Effects of vanadium-containing compounds on membrane lipids and on microdomains used in receptor-mediated signaling.
PubMed:Inhibition of protein tyrosine phosphatase 1B and alkaline phosphatase by bis(maltolato)oxovanadium (IV).
PubMed:Sarcoplasmic reticulum calcium ATPase is inhibited by organic vanadium coordination compounds: pyridine-2,6-dicarboxylatodioxovanadium(V), BMOV, and an amavadine analogue.
PubMed:The anti-diabetic effects and pharmacokinetic profiles of bis(maltolato)oxovanadium in non-diabetic and diabetic rats.
PubMed:Vanadate, an inhibitor of stromelysin and collagenase expression, suppresses collagen induced arthritis.
PubMed:Effect of bis (maltolato) oxovanadium (BMOV) in uric acid and sodium arsenite-induced vascular endothelial dysfunction in rats.
PubMed:Molecular mechanism of bis(maltolato)oxovanadium(IV)-induced insulin signaling in 3T3-L1 and IM9 cells: impact of dexamethasone.
PubMed:Involvement of insulin-like growth factor type 1 receptor and protein kinase Cdelta in bis(maltolato)oxovanadium(IV)-induced phosphorylation of protein kinase B in HepG2 cells.
PubMed:Effect of bis(maltolato) oxovanadium on experimental vascular endothelial dysfunction.
PubMed:Prevention of diabetes by inhibition of tyrosine phosphatases.
PubMed:Differences in plasma homocysteine levels between Zucker fatty and Zucker diabetic fatty rats following 3 weeks oral administration of organic vanadium compounds.
PubMed:Inhibition of protein tyrosin phosphatase improves vascular endothelial dysfunction.
PubMed:The vanadyl (VO2+) chelate bis(acetylacetonato)oxovanadium(IV) potentiates tyrosine phosphorylation of the insulin receptor.
PubMed:Structure and conformation of bis(acetylacetonato)oxovanadium(IV) and bis(maltolato)oxovanadium(IV) in solution determined by electron nuclear double resonance spectroscopy.
PubMed:Royal Society of Chemistry--sixth international symposium on applied bioinorganic chemistry.
PubMed:Coordination chemistry and insulin-enhancing behavior of vanadium complexes with maltol C6H6O3 structural isomers.
PubMed:New insights into the interactions of serum proteins with bis(maltolato)oxovanadium(IV): transport and biotransformation of insulin-enhancing vanadium pharmaceuticals.
PubMed:A nonspecific phosphotyrosine phosphatase inhibitor, bis(maltolato)oxovanadium(IV), improves glucose tolerance and prevents diabetes in Zucker diabetic fatty rats.
PubMed:Synthesis, structural properties and insulin-enhancing potential of bis(quercetinato)oxovanadium(IV) conjugate.
PubMed:Effects of three and eight weeks oral administration of bis(maltolato)oxovanadium(IV) on plasma homocysteine and cysteine levels in streptozotocin-induced diabetic rats.
PubMed:The permeability and cytotoxicity of insulin-mimetic vanadium compounds.
PubMed:[Hypoglycemic effects of bis(maltolato)oxovanadium administered by different routes upon diabetic rats].
PubMed:Comparison of anti-hyperglycemic effect amongst vanadium, molybdenum and other metal maltol complexes.
PubMed:Streptozotocin-induced alterations in rat liver Golgi complexes are ameliorated by BMOV [Bis(maltolato)oxovanadium(IV)] activity.
PubMed:The tyrosine phosphatase inhibitor bis(maltolato)oxovanadium attenuates myocardial reperfusion injury by opening ATP-sensitive potassium channels.
PubMed:Tyrosine phosphatase inhibition augments collateral blood flow in a rat model of peripheral vascular disease.
PubMed:Chronic glucose-lowering effects of rosiglitazone and bis(ethylmaltolato)oxovanadium(IV) in ZDF rats.
PubMed:Mechanism of insulin sensitization by BMOV (bis maltolato oxo vanadium); unliganded vanadium (VO4) as the active component.
PubMed:The influence of BMOV [bis(maltolato)oxovanadium(IV)] on biochemical and morphological alterations characteristic for streptozotocin-diabetic rat liver Golgi complexes.
PubMed:Preparation and characterization of vanadyl complexes with bidentate maltol-type ligands; in vivo comparisons of anti-diabetic therapeutic potential.
PubMed:Mechanisms by which bis(maltolato)oxovanadium(IV) normalizes phosphoenolpyruvate carboxykinase and glucose-6-phosphatase expression in streptozotocin-diabetic rats in vivo.
PubMed:The influence of a new vanadium compound, bis(2,2'-bipyridine)oxovanadium(IV) sulphate on liver golgi complexes from control and streptozotocin-diabetic rats.
PubMed:Oral treatment with vanadium of Zucker fatty rats activates muscle glycogen synthesis and insulin-stimulated protein phosphatase-1 activity.
PubMed:Vanadium increases GLUT4 in diabetic rat skeletal muscle.
PubMed:Influence of chelation and oxidation state on vanadium bioavailability, and their effects on tissue concentrations of zinc, copper, and iron.
PubMed:Bis(maltolato)oxovanadium(IV) inhibits the activity of PTP1B in Zucker rat skeletal muscle in vivo.
PubMed:Effect of chronic treatment with Bis(maltolato)oxovanadium (IV) in rat model of non-insulin-dependent-diabetes.
PubMed:Structural origins of the insulin-mimetic activity of bis(acetylacetonato)oxovanadium(IV).
PubMed:In vivo effects of insulin and bis(maltolato)oxovanadium (IV) on PKB activity in the skeletal muscle and liver of diabetic rats.
PubMed:In vivo effects of vanadium in diabetic rats are independent of changes in PI-3 kinase activity in skeletal muscle.
PubMed:Insulin-enhancing vanadium(III) complexes.
PubMed:Lack of in vivo effect of vanadium on GLUT4 translocation in white adipose tissue of streptozotocin-diabetic rats.
PubMed:Effect of vanadium on insulin sensitivity and appetite.
PubMed:Effect of vanadium(IV) compounds in the treatment of diabetes: in vivo and in vitro studies with vanadyl sulfate and bis(maltolato)oxovandium(IV).
PubMed:In vivo effects of vanadium on GLUT4 translocation in cardiac tissue of STZ-diabetic rats.
PubMed:Biochemical and morphological alterations in rat liver Golgi complexes after treatment with bis(maltolato)oxovanadium(IV) [BMOV] or maltol alone.
PubMed:Selective phosphotyrosine phosphatase inhibition and increased ceramide formation is associated with B-cell death by apoptosis.
PubMed:Mechanisms of apoptosis in embryonic cortical neurons (E6 and E7) in culture involve lipid signalling, protein phosphorylation and caspase activation.
PubMed:Effects of bis(maltolato) oxovanadium (IV) on protein serine kinases in skeletal muscle of streptozotocin-diabetic rats.
PubMed:Tyrosine phosphorylation and morphological transformation induced by four vanadium compounds on MC3T3E1 cells.
PubMed:Acute and chronic oral administration of bis(maltolato)oxovanadium(IV) in Zucker diabetic fatty (ZDF) rats.
PubMed:Effects of vanadium complexes with organic ligands on glucose metabolism: a comparison study in diabetic rats.
PubMed:Influence of bis(maltolato)oxovanadium(IV) on activity of galactosyltransferase (GalT) and morphology of rat liver Golgi apparatus in control and streptozotocin diabetes.
PubMed:Kinetic analysis and comparison of uptake, distribution, and excretion of 48V-labeled compounds in rats.
PubMed:Glucose-lowering properties of vanadium compounds: comparison of coordination complexes with maltol or kojic acid as ligands.
PubMed:Maltol complexes of vanadium (IV) and (V) regulate in vitro alkaline phosphatase activity and osteoblast-like cell growth.
PubMed:Role of oxidative stress in the action of vanadium phosphotyrosine phosphatase inhibitors. Redox independent activation of NF-kappaB.
PubMed:Acute and chronic response to vanadium following two methods of streptozotocin-diabetes induction.
PubMed:A polymer-based drug delivery system for the antineoplastic agent bis(maltolato)oxovanadium in mice.
PubMed:Effects of bis(maltolato)oxovanadium(IV) are distinct from food restriction in STZ-diabetic rats.
PubMed:Intracellular CD22 rapidly moves to the cell surface in a tyrosine kinase-dependent manner following antigen receptor stimulation.
PubMed:Characterization of a CD43/leukosialin-mediated pathway for inducing apoptosis in human T-lymphoblastoid cells.
PubMed:Characterization of the Potent Insulin Mimetic Agent Bis(maltolato)oxovanadium(IV) (BMOV) in Solution by EPR Spectroscopy.
PubMed:Effects of low and high dose administration of bis(maltolato)oxovanadium(IV) on fa/fa Zucker rats.
PubMed:Oxidation Kinetics of the Potent Insulin Mimetic Agent Bis(maltolato)oxovanadium(IV) (BMOV) in Water and in Methanol.
PubMed:Vanadium chemistry and biochemistry of relevance for use of vanadium compounds as antidiabetic agents.
PubMed:Skeletal muscle mitogen-activated protein kinases and ribosomal S6 kinases. Suppression in chronic diabetic rats and reversal by vanadium.
PubMed:Lineage-specific induction of B cell apoptosis and altered signal transduction by the phosphotyrosine phosphatase inhibitor bis(maltolato)oxovanadium(IV).
PubMed:Comparison of the glucose-lowering properties of vanadyl sulfate and bis(maltolato)oxovanadium(IV) following acute and chronic administration.
PubMed:Bis(maltolato)oxovanadium(IV) attenuates hyperinsulinemia and hypertension in spontaneously hypertensive rats.
PubMed:Improvement in cardiac dysfunction in streptozotocin-induced diabetic rats following chronic oral administration of bis(maltolato)oxovanadium(IV).
PubMed:Glucose-lowering effects of a new organic vanadium complex, bis(maltolato)oxovanadium(IV).
PubMed:Bis(maltolato)oxovanadium(IV) is a potent insulin mimic.
 
Notes:
a hypoglycemic agentt.
Please share your Comments.
Email Address:
Top of Page Home
Copyright © 1980-2021 The Good Scents Company (tgsc) ™ Disclaimer Privacy Policy